Slack Potassium Channel Inhibitors for the Treatment of Childhood Epilepsies

用于治疗儿童癫痫的松弛钾通道抑制剂

基本信息

  • 批准号:
    10037654
  • 负责人:
  • 金额:
    $ 43.45万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-01-01 至 2021-12-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Potassium channels are critical for life, playing a variety of physiological roles including control of solute balance, cell volume, and cellular excitability. In excitable cells potassium channels are involved in setting membrane potential and modulation of action potentials. Slack channels, encoded by KCNT1, are members of the Slo family of potassium channels, comprised of Slo1 (Maxi-K), Slo2.1 (Slick), Slo2.2 (Slack) and Slo3, a sperm-specific channel. Recently, multiple studies have identified ~30 mutations in Slack channels that are associated with a variety of epilepsies, most frequently Malignant Migrating Partial Seizures of Infancy (MMPSI). MMPSI are extremely severe, pharmacoresistant, and typically fatal during the first year of life. Slack variants associated with these epilepsies are found in three clusters: the pore of the channel, and in two separate carboxy-terminal regulatory regions, Regulator of Conductance of K+ (RCK) and NAD+ binding domains. Interestingly, these mutations are dominant, gain-of-function mutations resulting in a higher degree of Slack channel activity. Although the exact mechanism by which over-activity of Slack leads to MMPSI and other, less severe epilepsies is not understood, we hypothesize that specific inhibitors of Slack channels may provide a viable anti-epileptic strategy. Thus, the aims of this proposal are to build a hit-discovery and characterization infrastructure focused on providing an ability to conduct an 110,000 compound screen on wild-type Slack and 3 MMPSI-associated mutants, one from each of the three clusters (R21 Phase). We will utilize this infrastructure and a focused hit-to- leads medicinal-chemistry effort, including assays and strategies geared toward enhancing drug-likeness, to support the discovery and characterization of Slack-specific inhibitors (R33 Phase). The goal of the proposed research is to discover and validate at least two small molecule scaffolds, providing a platform for development of in vivo-active Slack inhibitors and a foundation for a therapeutically focused lead optimization effort.
摘要 钾通道对生命至关重要,发挥着多种生理作用,包括控制溶质平衡, 细胞体积和细胞兴奋性。在可兴奋细胞中,钾通道参与膜的形成 电位和动作电位的调节。由KCNT 1编码的Slack通道是Slo家族的成员 钾通道,包括Slo 1(Maxi-K),Slo2.1(Slick),Slo2.2(Slack)和Slo 3,精子特异性 频道最近,多项研究已经在Slack通道中发现了约30种突变,这些突变与以下疾病相关: 各种癫痫,最常见的是婴儿恶性游走性部分性癫痫发作(MMPSI)。MMPSI是 非常严重,耐药性,通常在生命的第一年内致命。相关的松弛变体 与这些癫痫被发现在三个集群:孔的通道,并在两个单独的羧基末端 调节区域,K+电导调节器(RCK)和NAD+结合结构域。有趣的是,这些 突变是显性的,功能获得性突变导致更高程度的Slack通道活性。 尽管Slack过度活动导致MMPSI和其他不太严重的癫痫的确切机制 我们假设Slack通道的特异性抑制剂可能提供一种可行的抗癫痫药物, 战略因此,本提案的目的是建立一个命中发现和表征基础设施, 提供对野生型Slack和3种MMPSI相关的化合物进行110,000种化合物筛选的能力 突变体,来自三个簇(R21相)中的每一个。我们将利用这一基础设施和集中打击- 领导药物化学工作,包括旨在增强药物相似性的测定和策略, 支持Slack特异性抑制剂(R33阶段)的发现和表征。建议的目标 研究是发现和验证至少两个小分子支架,为开发提供平台 体内活性Slack抑制剂的研究,以及以治疗为重点的先导化合物优化工作的基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kyle A Emmitte其他文献

Kyle A Emmitte的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kyle A Emmitte', 18)}}的其他基金

Discovery of small molecule activators of the Slack potassium channel for use as cell-based probes for the study of fragile X syndrome
发现 Slack 钾通道小分子激活剂,可用作脆性 X 综合征研究的细胞探针
  • 批准号:
    10308492
  • 财政年份:
    2020
  • 资助金额:
    $ 43.45万
  • 项目类别:
Discovery and Optimization of Selective Negative Allosteric Modulators of mGluR3
mGluR3 选择性负变构调节剂的发现和优化
  • 批准号:
    8547109
  • 财政年份:
    2012
  • 资助金额:
    $ 43.45万
  • 项目类别:
Discovery and Optimization of Selective Negative Allosteric Modulators of mGluR3
mGluR3 选择性负变构调节剂的发现和优化
  • 批准号:
    8417320
  • 财政年份:
    2012
  • 资助金额:
    $ 43.45万
  • 项目类别:
Small Molecular
小分子
  • 批准号:
    8337501
  • 财政年份:
    2008
  • 资助金额:
    $ 43.45万
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 43.45万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 43.45万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 43.45万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 43.45万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 43.45万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 43.45万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 43.45万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 43.45万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 43.45万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 43.45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了